Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections

Mazzei, Teresita; Cassetta, Maria Iris; Fallani, Stefania; Arrigucci, Silvia; Novelli, Andréa

doi:10.1016/j.ijantimicag.2006.05.019

Cited by 65 publications

(56 citation statements)

References 30 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has to be underlined that these beneficial immunological properties of FT are observed at FT concentration much lower than those usually detected after FT administration in patients for treatment of uncomplicated UTIs (6). All of these data permit the conclusionthat both uremic-infectedpatients and immunocompromised patients might additionally benefit from the immunotnodulatingproperties of FT.…”

Section: Discussionmentioning

confidence: 95%

Role of Fosfomycin Tromethamine in Modulating Non-Specific Defence Mechanisms in Chronic Uremic Patients towards ESBL-Producing Escherichia Coli

Tullio

Cuffini

Banche

et al. 2008

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Antimicrobial agents and polymorphonuclear cells (PMNs) have the potential to interact in such a way that improve the therapy for infectious diseases. In immunocompromised patients highly susceptible to microbial infections with high morbidity and mortality, several metabolic and functional alterations in PMNs, mostly related to microbicidal activity, are observed. Therefore, the antibiotic of choice should have a good antimicrobial effect without impairing host defences. The aim of this study is to evaluate in vitro effects of sub-inhibiting fosfomycin tromethamine (FT) concentrations on the primary functions of PMNs from healthy subjects and immunocompromised patients (haemodialysed and renal transplant recipients), against an ESBL-producing Escherichia coli, the most common aetiological agent in urinary tract infections (UTIs). FT is considered a first line drug in the eradication of UTIs due to its appropriate antimicrobial spectrum, oral bioavailability and minimal risk of microbial resistance. Our results provide evidence that FT is able to induce enhancement of the depressed phagocytic response of PMNs from patients on chronic haemodialysis and from renal transplant recipients, restoring their primary functions in vitro against ESBL-producing E. coll All these data permit the conclusion that uremic-infected patients might additionally benefit from the immunomodulating properties of FT.

show abstract

Section: Discussionmentioning

confidence: 95%

Role of Fosfomycin Tromethamine in Modulating Non-Specific Defence Mechanisms in Chronic Uremic Patients towards ESBL-Producing Escherichia Coli

Tullio

Cuffini

Banche

et al. 2008

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

“…In this respect, some studies have found that fosfomycin demonstrates concentration-dependent killing activity against strains of Escherichia coli and Proteus mirabilis in vitro as well as strains of S. pneumoniae in vivo [38,39]. However, other studies have noted timedependent bactericidal activity of fosfomycin against S. aureus strains in vitro [32,40].…”

Section: Pharmacodynamic Characteristics Of Fosfomycinmentioning

confidence: 99%

“…Fosfomycin has also exhibited a rather prolonged post-antibiotic effect (PAE) in vitro against strains of E. coli and P. mirabilis, varying between 3.4 h and 4.7 h depending on the drug concentration applied [38]. However, against strains of S. aureus a relatively shorter PAE has been observed (0.5-…”

Section: Pharmacodynamic Characteristics Of Fosfomycinmentioning

confidence: 99%

Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections

Roussos

Karageorgopoulos

Samonis

et al. 2009

International Journal of Antimicrobial Agents

162

151

View full text Add to dashboard Cite

show abstract

“…Fosfomycin ([(2R,3S)-3-methyloxiran-2-yl]phosphonic acid), of the family of phosphonic antibiotics, is an unique antibiotic of a chemical structure unrelated to those of any other known antibacterial agent [4,21,29,33] Current Issues in Pharmacy and Medical Sciences 4.7 h, depending on the applied drug concentration [28]. Fosfomycin also exerts time-dependent bactericidal activity against both Gram-negative and Gram-positive pathogens [29].…”

Section: Fosfomycin -General Informationmentioning

confidence: 99%

Overview on fosfomycin and its current and future clinical significance

Chudzik-Rząd

Andrzejczuk

Rzad³

et al. 2015

Current Issues in Pharmacy and Medical Sciences

View full text Add to dashboard Cite

Fosfomycin is an old antibiotic with a unique chemical structure and with broadspectrum activity against numerous bacterial pathogens, both Gram-positive and Gramnegative, including resistant and multi-resistant strains. This antibiotic was accepted into clinical practice in the early 1970s. Its use, however, has been limited for several years for treating mainly lower uncomplicated urinary tract infections (in the form of fosfomycin trometamol taken orally). Nowadays, many clinicians and scientists are looking at this antibacterial drug for its employment in the treatment of severe infections caused by multi-resistant bacteria. Fosfomycin as an intravenous formulation (fosfomycin disodium) achieves clinically relevant concentrations in the serum and the cerebrospinal fluid, in kidney, bladder wall, prostate, lungs, bone and heart valves tissues, as well as in inflamed tissues and abscess fluid. The available clinical studies confirmed the efficacy of intravenous fosfomycin for the management of severe infections caused by multiresistant pathogens.

show abstract

Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections

Cited by 65 publications

References 30 publications

Role of Fosfomycin Tromethamine in Modulating Non-Specific Defence Mechanisms in Chronic Uremic Patients towards ESBL-Producing Escherichia Coli

Role of Fosfomycin Tromethamine in Modulating Non-Specific Defence Mechanisms in Chronic Uremic Patients towards ESBL-Producing Escherichia Coli

Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections

Overview on fosfomycin and its current and future clinical significance

Contact Info

Product

Resources

About